Physician profile
Onweli E Ogbolu
NPI 1336301423
$1,341.57
in general payments reported to CMS, 2019-2025
22 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.24 · 2022: $69.89 · 2023: $219 · 2024: $480 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,195 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.36 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $198.90 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $161.21 | 2019-2025 | Tavneos, Parsabiv |
| Novartis Pharmaceuticals Corporation | $109.28 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $90.06 | 2023-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.38 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $73.88 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $57.12 | 2023-2024 | Auryxia, Vafseo |
| Lilly USA, LLC | $57.11 | 2023-2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $55.05 | 2024 | Acthar |
| Calliditas Therapeutics US INC. | $53.88 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $53.56 | 2022-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $52.64 | 2024 | |
| Scpharmaceuticals INC. | $47.57 | 2025 | |
| Aurinia Pharma U.S., INC. | $41.35 | 2022-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $39.94 | 2022-2023 | Velphoro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $32.41 | 2023-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.03 | 2024-2025 | |
| Genentech USA, INC. | $28.89 | 2025 | Gazyva |
| Veloxis Pharmaceuticals, INC. | $23.69 | 2019 | |
| Apellis Pharmaceuticals, INC. | $21.04 | 2025 | |
| Novo Nordisk INC | $19.67 | 2025 | Wegovy |
| Horizon Therapeutics Plc | $18.91 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onweli Ogbolu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.